Clinical trial · Observational
Expression of DMBT1 in Colorectal Cancer Patients
Modification of the Expression and the Localization of DMBT1 (Deleted in Malignant Brain Tumor 1) in Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Although colorectal cancer is a preventable and curable disease if early stage tumors are removed, it is still the fourth cause of cancer worldwide and the second leading cause of death in many industrialized countries. The 5-year survival is about 55% often due to a late detection. Then, the identification of sensitive and specific molecular markers is therefore a major challenge for early diagnosis and prognosis of this disease. Preliminary work have reported variations in the expression of DMBT1 (deleted in malignant brain tumor 1), a glycoprotein co-secreted with mucins in the light of the glands, during several stages of colon carcinogenesis. The goal of this study is to study by mass spectrometry (MS), alterations in the repertoire of glycosylation of mucins from colorectal tumors of various stages, grades, and recurrence status.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| DMBT1 Protein, Human | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Detection of the expression of DMTB1 by immunohistochemistry | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Patients with colorectal cancer
- description
- Fresh tissue samples from individuals with colorectal carcinoma taken from the tumor as well as from resection margins will be used for the detection of a potential marker of carcinogenesis.
- interventionNames
- Other: Detection of the expression of DMTB1 by immunohistochemistry
- label
- Patients with adenomatous polyps
- description
- Fresh tissue samples from individuals with adenomatous polyps will be used for the detection of a potential marker of carcinogenesis.
- interventionNames
- Other: Detection of the expression of DMTB1 by immunohistochemistry
- label
- Control patients
- description
- Fresh tissue samples from individuals without colorectal carcinoma will be used as control.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * for colon cancer: patients surgically treated for colorectal cancer at the Group of hospitals of the Catholic Institute of Lille. * for adenomatous polyps : patients treated for adenomatous polyps at the Group of hospitals of the Catholic Institute of Lille. * for controls: patients surgically treated for diverticular disease at the Group of hospitals of the Catholic Institute of Lille. Exclusion Criteria: * none
References
Publications (0)
Data not yet available